Ocular Therapeutix, Inc. will present at the J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco.
Quiver AI Summary
Ocular Therapeutix, Inc. announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, CA. The presentation will take place on January 13 at 5:15 PM PT, featuring Pravin U. Dugel, MD, the Executive Chairman, President, and CEO of the company. Ocular Therapeutix focuses on developing innovative therapies for retinal diseases, including its product candidate AXPAXLI (axitinib intravitreal implant), currently in Phase 3 trials for wet age-related macular degeneration. Their pipeline also includes the FDA-approved product DEXTENZA and another candidate, PAXTRAVA, which is in Phase 2 for open-angle glaucoma. The presentation will be accessible via the company's website.
Potential Positives
- Ocular Therapeutix will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, highlighting the company's visibility and commitment to engaging with investors and stakeholders.
- The presentation will be led by the Executive Chairman, President, and CEO, Dr. Pravin U. Dugel, which emphasizes strong leadership representation at major industry events.
- Ocular Therapeutix's product candidate AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration, indicating progress in their pipeline and potential market impact.
- The company continues to leverage its proprietary ELUTYX technology in its product offerings, showcasing innovation that may enhance treatment options in ophthalmic medicine.
Potential Negatives
- There is no mention of any recent achievements or positive developments regarding the current clinical trials, which may raise concerns about the progress and efficacy of their lead product candidate, AXPAXLI.
- The press release lacks financial performance metrics or guidance, which could signal that the company is facing challenges that it is not publicly addressing.
- The announcement is primarily focused on an upcoming conference presentation, suggesting that the company may not have immediate newsworthy developments to share, potentially signaling stagnation in their operational updates.
FAQ
What is the date of Ocular Therapeutix's presentation at the J.P. Morgan Healthcare Conference?
Ocular Therapeutix will present on January 13, 2025.
Where will the J.P. Morgan Healthcare Conference take place?
The conference will be held in San Francisco, CA.
Who will present for Ocular Therapeutix at the conference?
Pravin U. Dugel, MD, will present as the Executive Chairman, President, and CEO.
How can I access the live presentation?
The live presentation can be accessed on the Ocular Therapeutix website under the Events and Presentations section.
What is AXPAXLI and its current clinical trial stage?
AXPAXLI is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here's a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- JEFFREY S. HEIER (Chief Scientific Officer) sold 2,948 shares.
- PETER KAISER (Chief Development Officer) sold 2,897 shares.
- SANJAY NAYAK (Chief Strategy Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 3,646 shares.
- PRAVIN DUGEL (See Remarks) has traded it 2 times. They made 0 purchases and 2 sales, selling 41,560 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OCUL Hedge Fund Activity
We have seen 76 institutional investors add shares of $OCUL stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ASSENAGON ASSET MANAGEMENT S.A. added 2,825,756 shares (+inf%) to their portfolio in Q3 2024
- GREAT POINT PARTNERS LLC removed 1,728,723 shares (-100.0%) from their portfolio in Q2 2024
- LOGOS GLOBAL MANAGEMENT LP removed 1,650,000 shares (-32.0%) from their portfolio in Q3 2024
- ACUTA CAPITAL PARTNERS, LLC removed 1,581,059 shares (-57.1%) from their portfolio in Q3 2024
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 1,056,092 shares (+inf%) to their portfolio in Q3 2024
- WOODLINE PARTNERS LP added 1,000,000 shares (+inf%) to their portfolio in Q3 2024
- INVESCO LTD. added 709,573 shares (+1545.9%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43
rd
Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA.
43
rd
Annual J.P. Morgan Healthcare Conference Presentation Details
Presentation Date: Monday, January 13, 2025
Presentation Time: 5:15 PM PT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: San Francisco, CA
The live presentation can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI (axitinib intravitreal implant, also known as OTX-TKI), Ocular's product candidate for retinal disease, is based on its ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular's pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA
, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA
are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI, PAXTRAVA, ELUTYX, and Ocular Therapeutix are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
